Forty Seven (NASDAQ:FTSV) Trading Up 17.5%

Share on StockTwits

Forty Seven Inc (NASDAQ:FTSV) was up 17.5% during trading on Monday . The stock traded as high as $7.66 and last traded at $7.52, approximately 288,539 shares were traded during mid-day trading. An increase of 24% from the average daily volume of 231,937 shares. The stock had previously closed at $6.40.

Several research analysts recently commented on FTSV shares. Roth Capital started coverage on Forty Seven in a research note on Wednesday, May 29th. They issued a “buy” rating and a $28.00 price objective for the company. Oppenheimer cut their target price on Forty Seven from $35.00 to $20.00 in a research note on Wednesday, August 14th. Zacks Investment Research raised Forty Seven from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Tuesday, May 14th. ValuEngine raised Forty Seven from a “hold” rating to a “buy” rating in a research note on Friday, August 16th. Finally, HC Wainwright set a $21.00 target price on Forty Seven and gave the stock a “buy” rating in a research note on Friday, July 12th. Nine analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $25.86.

The firm has a market capitalization of $200.70 million, a price-to-earnings ratio of -2.01 and a beta of 1.86. The business has a 50 day simple moving average of $8.79 and a 200-day simple moving average of $13.57.

Forty Seven (NASDAQ:FTSV) last issued its earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.05). Analysts predict that Forty Seven Inc will post -2.32 EPS for the current year.

In other Forty Seven news, Director Jeffrey W. Bird purchased 750,000 shares of the stock in a transaction dated Monday, July 22nd. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $6,000,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Lightspeed Venture Partners X, purchased 625,000 shares of the stock in a transaction dated Monday, July 22nd. The shares were acquired at an average price of $8.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. Corporate insiders own 37.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Schroder Investment Management Group acquired a new position in shares of Forty Seven in the second quarter valued at approximately $552,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Forty Seven by 2.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 709,796 shares of the company’s stock valued at $7,524,000 after purchasing an additional 14,591 shares during the period. Citadel Advisors LLC increased its holdings in shares of Forty Seven by 8.5% in the second quarter. Citadel Advisors LLC now owns 510,309 shares of the company’s stock valued at $5,409,000 after purchasing an additional 39,871 shares during the period. Bank of America Corp DE boosted its stake in shares of Forty Seven by 535.2% in the second quarter. Bank of America Corp DE now owns 64,170 shares of the company’s stock valued at $680,000 after buying an additional 54,067 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Forty Seven by 1.2% in the second quarter. Vanguard Group Inc. now owns 499,451 shares of the company’s stock valued at $5,294,000 after buying an additional 5,741 shares in the last quarter. Institutional investors and hedge funds own 48.49% of the company’s stock.

About Forty Seven (NASDAQ:FTSV)

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Featured Story: What is an economic bubble?

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Enova International  Downgraded to “Hold” at Zacks Investment Research
Enova International Downgraded to “Hold” at Zacks Investment Research
NAGA  Market Cap Reaches $1.74 Million
NAGA Market Cap Reaches $1.74 Million
Monero Tops 24-Hour Trading Volume of $87.24 Million
Monero Tops 24-Hour Trading Volume of $87.24 Million
IOTA  Price Tops $0.25
IOTA Price Tops $0.25
NEO  Reaches Market Capitalization of $485.56 Million
NEO Reaches Market Capitalization of $485.56 Million
SmartMesh  Trading 4.6% Lower  Over Last Week
SmartMesh Trading 4.6% Lower Over Last Week


 
© 2006-2019 Zolmax.